Ar­ray walks back its FDA pitch on binime­tinib, de­rail­ing plans for com­mer­cial launch

Ron Squar­er, CEO

Ar­ray Bio­Phar­ma has some ex­plain­ing to do. Fif­teen months af­ter the Boul­der, CO-based biotech said that it had the da­ta need­ed for its first ap­proval of binime­tinib for NRAS-pos­i­tive melanoma, ex­ecs are walk­ing back the ap­pli­ca­tion and its plans for a launch.

In a state­ment out Sun­day evening, Ar­ray $AR­RY said that af­ter get­ting feed­back from the FDA, ex­ecs  “con­clud­ed that the clin­i­cal ben­e­fit demon­strat­ed in the Phase 3 NEMO clin­i­cal tri­al would not be found suf­fi­cient to sup­port ap­proval of the NRAS-mu­tant melanoma NDA.”

Shares of Ar­ray dropped 26% in pre-mar­ket trad­ing Mon­day.

Michael Schmidt at Leerink was not pleased. He not­ed:

While NRAS+ melanoma was on­ly a small val­ue dri­ver for the com­pa­ny, we think this comes as a sur­prise to in­vestors and is a clear set­back for the com­pa­ny and mgmt.’s reg­u­la­to­ry and com­mer­cial strat­e­gy. Re­call, man­age­ment planned to build a com­mer­cial in­fra­struc­ture and vis­i­bil­i­ty with cus­tomers this year around the launch in NRAS+ melanoma, which would al­so be in prepa­ra­tion for the planned launch in 2018 of binime­tinib/en­co­rafenib in more com­pet­i­tive BRAF+ melanoma, which is AR­RY’s main val­ue dri­ver.

It was a much dif­fer­ent sto­ry back in late 2015 when CEO Ron Squar­er said that their MEK block­er hit the pri­ma­ry end­point on pro­gres­sion-free sur­vival, with the drug arm reg­is­ter­ing 2.8 months com­pared to 1.5 months for a group on dacar­bazine. It didn’t look like much, but Ar­ray said it was plen­ty to take to the FDA.

In the sum­mer of 2016, though, the biotech al­so con­ced­ed that the drug had not sig­nif­i­cant­ly im­proved over­all sur­vival.

Ar­ray has had plen­ty of ups and downs with the drug. No­var­tis had part­nered with the com­pa­ny, but punt­ed the pro­gram when they ex­e­cut­ed a big as­set swap with Glax­o­SmithK­line. Pierre Fab­ry then took their spot, but Ar­ray held on to US com­mer­cial rights.

Ar­ray is plan­ning to file binime­tinib for BRAF-mu­tant melanoma in a few months.

Last fall the biotech re­port­ed that a com­bo of en­co­rafenib (LGX818) plus binime­tinib beat out a so­lo BRAF in­hibitor, Zelb­o­raf (ve­mu­rafenib), with a me­di­an pro­gres­sion-free sur­vival rate of 14.9 months vs. 7.3 months in the con­trol arm for BRAF-mu­tant melanoma pa­tients. There was a hitch, though, as the pair-up showed a me­di­an PFS of 14.9 months ver­sus 9.6 months for en­co­rafenib alone, which was not sta­tis­ti­cal­ly sig­nif­i­cant.

Un­lock­ing ESG strate­gies for growth with Gilead Sci­ences

RBC Capital Markets explores what is material in ESG for biopharma companies with the ESG leads at Gilead Sciences. Gilead has long focused on sustainability but recognized a more robust framework was needed. Based on a materiality assessment, Gilead’s ESG strategy today focuses first on drug access and pricing, while also addressing D&I and climate change. Find out why Gilead’s board is “acutely aware” of the contribution that ESG makes to firm’s overall success.

What con­tro­ver­sy? Eli Lil­ly plots Alzheimer's BLA fil­ing lat­er this year as FDA taps more an­ti-amy­loid drugs as break­throughs

The FDA is keeping the good news coming for Alzheimer’s drug developers. And Eli Lilly is taking them up on it.

Amid continued controversy around whether Biogen’s new flagship drug, Aduhelm, should have been approved at all — and swelling, heated debates surrounding its $56,000 price tag — the agency had no issue handing them and their Japanese partner Eisai a breakthrough therapy designation for a second anti-amyloid beta antibody, lecanemab, late Wednesday.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

New FDA doc­u­ments show in­ter­nal dis­sent on Aduhelm ap­proval

In a lengthy review document and a pair of memos from top officials, the FDA released on Tuesday night its most detailed argument yet for approving Biogen’s intensely controversial Alzheimer’s drug aducanumab.

The documents amount to an agency attempt to quench the firestorm their decision kindled, as outside advisors members resigned and experts warned that an unproven drug now could stretch Medicare’s budget to a breaking point. Ultimately, the documents show how CDER director Patrizia Cavazzoni and Office of New Drugs director Peter Stein both concurred with FDA neuroscience head Billy Dunn on the accelerated approval while the staff at FDA’s Office of Biostatistics did not think an approval was warranted.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

Hervé Hoppenot, Incyte CEO (Jeff Rumans)

ODAC echoes FDA con­cern over In­cyte PD-1, as Paz­dur sig­nals broad­er shift for ac­cel­er­at­ed ap­proval

After the FDA lambasted their PD-1 ahead of an adcomm earlier this week, Incyte ran into new trouble Thursday as ODAC panelists voted against an accelerated OK by a wide margin.

Members of the Oncologic Drugs Advisory Committee recommended with a 13-4 vote to defer a regulatory decision on Incyte’s retifanlimab until after more data can be collected from a placebo-controlled trial. The PD-1 therapy is due for a PDUFA date in late July after receiving priority review earlier this year.

Karen Flynn, Catalent

Q&A: When the pan­dem­ic struck, Catal­en­t's CCO had just joined the team

Karen Flynn came aboard Catalent’s team just in time.

The company was going through a surge of changes, and she had been brought over from her role as CCO of West Pharmaceutical Services to serve in the same capacity for the New Jersey-based CDMO. Then a few months later, the pandemic was in full-force.

Since then, Catalent’s been in hyper-expansion mode. In early May, it acquired Promethera’s Hepatic Cell Therapy Support SA subsidiary and its 32,40-square-foot facility in Gosselies, Belgium. Prior to that, the company acquired Belgian CDMO Delphi Genetics, wrapped up the expansion of an already-existing site in Madison, WI and added an ultra-low temperature freezer partner in Sterling. As Emergent has botched millions of doses of AstraZeneca’s vaccine, the company has swooped in to move that production to its Maryland plant as well.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

Richard Pazdur (vis AACR)

FDA en­cour­ages in­clud­ing in­cur­able can­cer pa­tients in tri­als, re­gard­less of pri­or ther­a­pies

The FDA on Thursday called to include those with incurable cancers (when there is no potential for cure or for prolonged/near normal survival) in appropriate clinical trials, regardless of whether they have received existing alternative treatments.

Historically, many cancer clinical trials have required that participating patients previously received multiple therapies, according to Richard Pazdur, director of the FDA’s Oncology Center of Excellence.

On heels of Aduhelm ap­proval, Bris­tol My­ers jumps back in­to Alzheimer's race

Bristol Myers Squibb last put major resources behind an Alzheimer’s drug nearly a decade ago, when their own attempt at targeting amyloid flamed out in mid-stage studies. They invented another molecule, a Tau-targeted antibody, but jettisoned it to Biogen in 2017 as they dropped out of neuroscience altogether.

But on Thursday, the New York pharma announced they were getting back in the game. Bristol Myers exercised an $80 million option to bring a tau-targeted antibody from Prothena into a Phase I study. The opt-in, which Bristol Myers triggered ahead of analyst expectations, opens the door for another $1.7 billion in milestones down the road.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 110,100+ biopharma pros reading Endpoints daily — and it's free.

James Peyer, Cambrian

Can a cell ther­a­py treat mus­cu­lar dy­s­tro­phy? A Ger­man bil­lion­aire's an­ti-ag­ing start­up is try­ing to find out

Gene therapy companies have faced huge hurdles trying to deliver healthy genes into muscular dystrophy patients’ muscle cells, so here’s an idea: Why don’t we just replace the muscle cells themselves?

Over the last two years, Vita Therapeutics has been exploring that possibility, building on early stem cell work from Johns Hopkins professor Peter Andersen. And on Tuesday they announced a $32 million Series A to begin to move their first therapy into the clinic, where they hope it will help rebuild muscle in patients with a type of dystrophy that afflicts the arms and legs.

Emma Walmsley (GSK via investor day livestream)

Mul­ti­va­lent mR­NA vac­cines, I/O 3.0, long-act­ing HIV drugs: The $46B game is on for the new Glax­o­SmithK­line

To understand the new GlaxoSmithKline that Emma Walmsley is promising to usher in, one must see through the old GSK.

“We know this has been a company that has perennially disappointed when you look at the first half of the last decade,” the CEO said in one of her final remarks at the long-anticipated investor day.

But after four years of strategic transformation and investment, her top team is ready to take the wraps off a shiny new version of the Big Pharma that, among other things, will strive to deliver £33 billion ($46 billion) in annual sales by 2031. It will start with a planned demerger of the consumer health business into a separate company in the middle of next year, while the new GSK retains a 20% stake as a “short-term financial investment.”